文献速递肺结节与肺癌

纳武利尤单抗联合伊匹木单抗对比卡铂双药一线治疗老年或ECOG 2分晚期NSCLC的III期ENERGY研究

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
PubMed 文献 · Lancet Respir Med · 2024-10-29

GFPC 08-2015 ENERGY研究在法国30家中心纳入217例晚期NSCLC患者(≥70岁或ECOG 2分),随机接受纳武利尤单抗联合伊匹木单抗或卡铂双药化疗。

要点

  • 总体人群联合组与化疗组OS无显著差异,研究因无效提前终止。

核心结论

  • 研究未显示纳武利尤单抗联合伊匹木单抗在总体研究人群中优于铂类双药化疗。
  • 在≥70岁且ECOG PS 0-1的NSCLC亚组中,联合治疗较铂类双药显示更好生存,值得进一步研究。
  • 研究因无效提前终止,主要和次要终点把握度不足。

研究设计与样本

  • 开放标签、多中心、随机、对照III期试验,在法国30家医院和癌症中心进行。
  • 纳入IV期组织学证实的NSCLC、无已知致癌驱动改变,且≥70岁ECOG 0-2或<70岁ECOG 2的患者。
  • 2018年2月12日至2020年12月15日随机分配217例患者,最终分析纳入216例(联合组109例,化疗组107例),中位年龄74岁(IQR 70-78)。
  • 按1:1随机分配接受纳武利尤单抗联合伊匹木单抗或铂类双药化疗(卡铂+培美曲塞或卡铂+紫杉醇)。
  • 主要终点为总生存期,次要终点包括无进展生存期和安全性。

主要发现

  • 未报告新的安全性信号。

关键数值与推荐

  • 化疗组最常见≥3级不良事件为中性粒细胞减少(28/103例,27%)。
  • 联合组最常见≥3级不良事件为内分泌疾病(5/105例,5%)、心脏疾病(10/105例,10%)和胃肠道疾病(11/105例,11%)。

临床怎么用

  • 对≥70岁且ECOG PS 0-1的晚期NSCLC患者,纳武利尤单抗联合伊匹木单抗可作为一线治疗选择之一。
  • ECOG PS 2分的老年患者一线不推荐纳武利尤单抗联合伊匹木单抗。
  • 临床决策需结合年龄和ECOG PS进行分层。

局限性

  • 研究因无效提前终止,主要和次要终点把握度不足。
  • 研究仅纳入法国患者,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or those with an ECOG performance status of 2 are scarce. We aimed to test the superiority of the PD-1 antibody nivolumab and the CTLA-4 antibody ipilimumab over platinum-based doublet chemotherapy as first-line treatment in patients with NSCLC aged 70 years or older or with an ECOG performance status of 2. METHODS: This open-label, multicentre, randomised, controlled, phase 3 trial was done at 30 hospitals and cancer centres in France. Eligible patients had stage IV histologically proven NSCLC, with no known oncogenic alterations, and were either aged 70 years or older with ECOG performance status of 0-2 or younger than 70 years with an ECOG performance status of 2. Patients were randomly assigned (1:1) centrally, using a computer-generated algorithm stratified by age (<70 vs ≥70 years), ECOG performance status (0-1 vs 2), and histology (squamous vs non-squamous) to receive nivolumab plus ipilimumab or platinum-based doublet chemotherapy (carboplatin [area under the curve ≤700 mg] plus pemetrexed [500 mg/m2 intravenous infusion every 3 weeks] or carboplatin [on day 1; area under the curve ≤700 mg] plus paclitaxel [90 mg/m2 as intravenous infusion on days 1, 5, and 15, every 4 weeks]). The primary endpoint was overall survival; secondary endpoints included progression-free survival and safety. All efficacy analyses were performed in the intention-to-treat population, which included all randomly assigned patients. Safety was analysed in the safety analysis set, which included all randomly assigned patients who received at least one dose of study treatment and who had at least one safety follow-up. The trial is registered with ClinicalTrials.gov, NCT03351361. FINDINGS: The trial was stopped early for futility on the basis of a pre-planned interim analysis after 33% of the expected events had occurred. Between Feb 12, 2018, and Dec 15, 2020, 217 patients were randomly assigned, of whom 216 patients were included in the final analysis, with 109 patients in the nivolumab plus ipilimumab group and 107 in the chemotherapy group; median age was 74 years (IQR 70-78). Median overall survival was 14·7 months (95% CI 8·0-19·7) in the nivolumab plus ipilimumab group and 9·9 months (7·7-12·3) in chemotherapy group (hazard ratio [HR] 0·85 [95% CI 0·62-1·16]). Among patients aged 70 years or older with an ECOG performance status of 0-1 (median age 76 years [IQR 73-79]), median overall survival was longer in the nivolumab plus ipilimumab group than the chemotherapy group: 22·6 months (95% CI 18·1-36·0) versus 11·8 months (8·9-20·5; HR 0·64 [95% CI 0·46-0·96]). Among patients with an ECOG performance status of 2 (median age 69 years [IQR 63-75]), median overall survival was 2·9 months (95% CI 1·4-4·8) in the nivolumab plus ipilimumab group versus 6·1 months (3·5-10·4) in the chemotherapy group (HR 1·32 [95% CI 0·82-2·11]). No new safety signals were reported. The most frequent grade 3 or worse adverse events were neutropenia (28 [27%] of 103 patients) in the chemotherapy group and endocrine disorders (five [5%] of 105 patients), cardiac disorders (ten [10%] patients), and gastrointestinal disorders (11 [11%] patients) in the nivolumab plus ipilimumab group. INTERPRETATION: The study showed no benefit of nivolumab plus ipilimumab combination in the overall study population. As a result of early stopping, the trial was underpowered for primary and secondary endpoints; however, the finding of better survival with nivolumab plus ipilimumab compared with platinum doublet in the subgroup of older patients with NSCLC with an ECOG performance status of 0-1 warrants further study. FUNDING: Bristol-Myers Squibb.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Léna H, Greillier L, Cropet C, et al. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med. 2024. PMID: 39486424. doi:10.1016/S2213-2600(24)00264-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。